Video

MicroRNA-34a in Hepatocellular Carcinoma

Amira Abdelhamid, assistant lecturer, German University in Cairo, discusses microRNA-34a and natural killer (NK) cells in hepatocellular carcinoma (HCC).

Amira Abdelhamid, assistant lecturer, German University in Cairo, discusses microRNA-34a and natural killer (NK) cells in hepatocellular carcinoma (HCC).

A recent study suggests that microRNA-34a could have a role in regulating cytotoxicity and development of the effector NK cells.

MicroRNA-34a has been previously found to be downregulated in HCC—which is also associated with tumor progression—but it has never been explored in the NK cells of patients with HCC, says Abdelhamid.

Results showed that in the NK cells of patients with HCC, forcing microRNA34a expression significantly increased NKG2D and cytotoxic perforin-1 mRNA levels.

Clinical trials have begun to investigate whether microRNA-34a can be used as a tumor suppressor, Abdelhamid adds.

Related Videos
Paolo Caimi, MD
Jennifer Scalici, MD
Steven H. Lin, MD, PhD
Anna Weiss, MD, associate professor, Department of Surgery, Oncology, associate professor, Cancer Center, University of Rochester Medicine
Roy S. Herbst, MD, PhD, Ensign Professor of Medicine (Medical Oncology), professor, pharmacology, deputy director, Yale Cancer Center; chief, Hematology/Medical Oncology, Yale Cancer Center and Smilow Cancer Hospital; assistant dean, Translational Research, Yale School of Medicine
Victor Moreno, MD, PhD
Haley M. Hill, PA-C, discusses preliminary data for zenocutuzumab in NRG1 fusion–positive non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses how physician assistants aid in treatment planning for NRG1-positive non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses DNA vs RNA sequencing for genetic testing in non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses current approaches and treatment challenges in NRG1-positive non–small cell lung cancer and pancreatic cancer.